# Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

> **NCT03122041** · PHASE4 · COMPLETED · sponsor: **University Medical Centre Ljubljana** · enrollment: 30 (actual)

## Conditions studied

- PCOS

## Interventions

- **DRUG:** Sitagliptin
- **BEHAVIORAL:** Lifestyle intervention

## Key facts

- **NCT ID:** NCT03122041
- **Lead sponsor:** University Medical Centre Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03122041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03122041, "Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03122041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*